AstraZeneca
Three appointments in AstraZeneca’s global media relations team
January 11, 2016Medical Communications AstraZeneca
Neil Burrows has joined as head of global media relations, following Esra Erkal-Paler’s promotion to head of global external communications.Burrows …
Dr Reddy’s relaunches generic Nexium in blue after AstraZeneca lawsuit
January 6, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, acid reflux, esomeprazole, lawsuit, purple pill
Dr Reddy’s has relaunched its generic version of AstraZeneca’s blockbuster heartburn drug Nexium in the US, changing the colour from …
FDA approves AstraZeneca’s gout drug Zurampic
December 23, 2015Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad
The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …
Three AstraZeneca drugs recommended by EMA committee
December 21, 2015Sales and Marketing AstraZeneca, Brilique, CHMP, EMA, Portrazza, Tagrisoo, lesinurad, lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several new drugs in its latest meeting, including …
AstraZeneca to buy majority share in Acerta Pharma
December 17, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers
Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …
AstraZeneca to acquire Takeda’s respiratory franchise
December 16, 2015Manufacturing and Production, Research and Development AstraZeneca, China, Takeda, investment, respiratory
AstraZeneca and Takeda have agreed a multi-million pound deal for AZ to acquire the Japanese firm’s core respiratory business, including …
AstraZeneca invests £75m to future-proof production facilities
December 15, 2015Manufacturing and Production AstraZeneca, manufacturing, production
AstraZeneca says it will invest £75m to future-proof a key production facility in Macclesfield, Cheshire. The upgrade to the 48-year-old …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
AstraZeneca deal to delve into the secretome
December 11, 2015Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome
MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
Early UK access for AstraZeneca lung cancer drug
December 9, 2015AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib
UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …
Top five pharma controversies of 2015 (so far)
November 20, 2015Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing
5. AstraZeneca forced to deny tax avoidance allegations
AstraZeneca earns ‘speedy’ FDA approval for lung cancer drug
November 13, 2015AZD9291, AstraZeneca, Tagrisso, lung cancer
The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …
AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
November 6, 2015Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers
AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …
FDA backs AZ gout drug despite safety concerns
October 26, 2015Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad
FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
